White House says U.S. will run out of money to fight pandemic if Congress doesn’t pass Covid funding bill

White House says U.S. will run out of money to fight pandemic if Congress doesn’t pass Covid funding bill


A healthcare worker prepares a dose of the Pfizer-BioNTech Covid-19 vaccine at a vaccination clinic in the Peabody Institute Library in Peabody, Massachusetts, on Wednesday, Jan. 26, 2022.

Vanessa Leroy | Bloomberg | Getty Images

The White House on Tuesday warned the U.S. won’t have enough booster shots and lifesaving Covid treatments for Americans if Congress fails to pass $22.5 billion in additional pandemic funding.

Senior Biden administration officials, on a call with reporters, said the U.S. could face another wave of Covid infections in the coming months, even as new cases and hospitalizations have dramatically declined from the peak of the unprecedented omicron surge in January. Infections are already on the rise again in major European nations, such as the U.K. and Germany. China is battling its worst outbreak since 2020.

The officials warned the funding is urgently needed to get ahead of another Covid wave. House Democrats last week stripped $15 billion in coronavirus funding, which was already less than Biden requested, from a broader spending bill after failing to reach a bipartisan agreement with Republicans. The GOP has insisted that Congress offset new Covid money by cutting funds for state and local governments allocated for the spring, a demand many Democrats were unwilling to accept.

The senior administration officials told reporters the federal government will not be able to purchase enough booster shots, vaccines that target specific variants or more antiviral pills beyond the 20 million already on order from Pfizer if more funding isn’t approved.

There is also no more funding for additional monoclonal antibody treatments, including an order planned for March 25, the officials said. If more funding doesn’t come through, the federal government will have to cut state allocations of monoclonal antibodies by more than 30% starting next week, they said.

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:

The federal government will also not be able to maintain sufficient Covid testing capacity beyond June in the event of another surge, the officials said. During the omicron wave, there was a run on at-home tests and in-person clinics, resulting in hourslong lines and empty pharmacy shelves.

Uninsured people will also no longer have coverage for Covid testing and treatments, according to the White House. The fund that covers them will stop accepting new claims a week from now, forcing health-care providers to either absorb the costs or turn patients away, the officials said. The fund will completely end in early April and the uninsured will no longer have coverage for vaccinations, they said.

Some investments made in surveillance of new Covid variants will also have to be wound down, the officials said, leaving the U.S. without the capabilities it needs to stay on top of how the virus is evolving. The emergence of the highly mutated omicron variant blindsided the U.S. and much of the world in November.

The White House said the money is also needed to fund the development of a vaccine that covers a range of Covid variants, and support the administration’s efforts to help increase the vaccination rate in developing nations. Without the money, the risk will rise that new variants will emerge, the officials said. Omicron emerged in South Africa and Botswana, and the delta variant was first identified in India.

 — CNBC’s Ylan Mui contributed to this report.



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More